Predict your next investment

Corporation
karex.com.my

See what CB Insights has to offer

About Karex

Karex, an investment holding company, manufactures and sells condoms under the Atlas, Carex, and INNO brand names.

Karex Headquarter Location

Lot 594, Persiaran Raja Lumu Pandamaran Industrial Estate

Selangor, 42000,

Malaysia

+603 3165 6688

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Karex News

Karex’s earnings to remain weak: CGS-CIMB

Jun 1, 2021

KUALA LUMPUR: Karex Bhd’s earnings are likely to be weak due to the increase in raw material prices (natural latex and chemicals), higher operating costs (such as Covid-19 related spending and shipping costs) and lower economies of scale (decline in overall utilisation rate for its operations), according to CGS-CIMB. Its analyst Walter Aw said the recent implementation of the third edition of Movement Control Order (MCO 3.0) should lower production volume of the condom manufacturer, dragged by the government directive for 40 per cent of the private sector’s workforce to work from home. “With the weaker-than-expected third quarter (Q3) results and the recent implementation of MC3.0, we cut our forecast on Karex’s financial year ending June 30, 2021 (FY21) to FY23 earnings per share (EPS) by 33 per cent to 87.7 per cent,” he said in a report today. Aw said this was due to lower production volume, higher operational expenditure and lower economies of scale. “Nevertheless, we still expect Karex to record a three-year EPS compound annual growth rate (CAGR) of 115.7 per cent between FY20 and 23F, driven by higher condom sales and maiden contribution from its glove venture from the second-half of FY22 onwards.” CGS-CIMB has reiterated an “add” call with a lower target price of 77 sen per share. Despite weakness in its near-term outlook, he said the “add” call on Karex was due to inelastic demand for condoms globally, established own brands in the condom market (One brand, Carex), and its position as the largest condom maker globally (in terms of production capacity). Potential re-rating catalysts include higher-than-expected average selling prices for condoms, and/or stronger-than-expected tender sales volumes. Downside risks include Covid-19 outbreak among Karex’s workers and/or stiff pricing competition in the condom tender market.

Karex Acquisitions

2 Acquisitions

Karex acquired 2 companies. Their latest acquisition was Global Production Corp on November 12, 2020.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

11/12/2020

$991

Acquired

1

2/3/2016

Subscribe to see more

$991

$99M

Subscribe to see more

10

Date

11/12/2020

2/3/2016

Investment Stage

Companies

Subscribe to see more

Valuation

$991

$991

Total Funding

$99M

Note

Acquired

Subscribe to see more

Sources

1

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.